On December 27, Antengene Corporation Limited (“Antengene”) announced that it had entered a global clinical collaboration with MSD to jointly conduct a stage I STAMINA-001 study. The study is aimed at evaluating the safety and tolerability of ATG-037 as a monotherapy as well as in combination with MSD’s anti-PD-1 therapy, pembrolizumab, for patients with locally advanced or metastatic solid tumors, to determine the appropriate dose for Phase II studies.
Under the terms of the agreement, the study will be conducted by Antengene, and MSD will provide pembrolizumab for the combination portions of the trial.
JunHe was engaged by Antengene to review and revise the transaction documents. The team was highly recognized for its efficient and prudent delivery of professional legal services.